- Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used for the treatment of hypertension, heart failure, and post-myocardial infarction management, playing a critical role in cardiovascular therapy across global healthcare systems
- The growing prevalence of hypertension and cardiovascular diseases, coupled with an aging population and increased awareness of preventive healthcare, are the primary drivers fueling demand in the Lisinopril market
- North America dominated the lisinopril market with the largest revenue share of 41.7% in 2024, owing to high disease prevalence, advanced healthcare infrastructure, widespread use of generic medications, and robust government support for chronic disease management. The U.S. contributed significantly to this growth, supported by large-scale prescriptions in outpatient and clinical settings
- Asia-Pacific is expected to be the fastest-growing region with a CAGR of 7.9% in the lisinopril market during the forecast period due to rising incidences of hypertension, improving healthcare access, increased generic drug manufacturing, and growing healthcare expenditure in countries such as India and China
- The tablet segment dominated the lisinopril market with a market share of 81.6% in 2024, favored for its stability, affordability, and high patient compliance
